Mixed Effects of Combining 2 Drugs, Canagliflozin & Liraglutide

Researchers examining the effects of combining the diabetes drugs canagliflozin, an SGLT2i, plus liraglutide, a GLP-1 RA, found that the combo was not much more effective than for lowering HBA1c than liraglutide alone, but the combo did have some weight loss benefits. Read more

How Safe is Dapagliflozin in the Elderly?

The SGLT-2 inhibitors are a relatively new treatment for type 2 diabetes, and the authors of this study felt their use had not yet been adequately studied in the elderly. They examined the effect of one SGLT-2 inhibitor, dapagliflozin (brand name Farxiga) to assess its effects on blood glucose control and kidney health in senior […]

Add an SGLT-2 Sooner Rather Than Later

For most people diagnosed with type 2 diabetes, the first treatments to be prescribed (aside from lifestyle changes like diet and exercise) are metformin or sulfonylureas. If these do not achieve the desired result, doctors may add additional medications. New research says that there is reason to add the SGLT-2 inhibitor early, as the second […]

Sitagliptin Shows Benefit in Diabetes Patients with COVID-19

The type 2 diabetes drug sitagliptin improves survival in patients with diabetes who have been hospitalized with COVID-19, according to Italian researchers. Patients who were given sitagliptin in addition to insulin had a mortality rate of 18 percent, versus 37 percent in similar patients who received insulin alone. Read more

Diabetes Drug Jardiance Shows Heart Failure Benefits

Jardiance (empagliflozin) has been studied for its use in people with heart failure. A study has found it shows effectiveness in patients with reduced ejection fraction (HFrEF). In heart failure with reduced ejection fraction, the heart muscle does not contract efficiently, and a smaller percentage of blood is pumped out of the heart than usual. […]

Newer Type 2 Drugs Increase Out-of-Pocket Costs for Medicare Patients

Recent diabetes guidelines have suggested giving type 2 diabetes patients newer glucose-lowering drugs like SGLT2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors, earlier in preference to older drugs like metformin and the sulfonylureas, due to their many benefits. However, for Medicare recipients, the out-of-pocket costs for these drugs are much higher. Read more

SGLT2 Inhibitors May Delay Kidney Disease

Drugs from the SGLT2 inhibitor class of diabetes medications have shown benefit in slowing progression of diabetic kidney disease, with a reduced risk of acute kidney injury (AKI) noted in research trials. People at high risk of AKIs who may be considering SGLT2 treatment should discuss the risks and benefits with their doctors. Read more

FDA Approves New Trulicity Dosages

The FDA has approved 2 additional doses of Eli Lilly’s Trulicity (dulaglutide) for treating type 2 diabetes. The approval of the new 3.0 mg and 4.5 mg doses of dulaglutide was based on clinical trial results showing benefits for A1C levels and weight loss. Read more

Metformin Helps Reduce Presurgical Stress

Surgical procedures cause both physical and mental stress on patients, and higher stress level is associated with an increased risk of complications and death. Researchers examined the effectiveness of metformin use before surgeries to reduce the risk of complications in patients with type 2 diabetes. Read more

Can Diabetes Drugs Fight COVID-19?

Multiple diabetes drugs are undergoing trials to see if they have a role to play in the fight against the novel coronavirus COVID-19. It’s already known that people with diabetes are at higher risk of serious complications from COVID-19; one reason may be that COVID-19 attacks the same bodily systems damaged by type 2 diabetes […]

Assessing the Heart Benefits of Ertugliflozin

The results from a major trial examining whether the diabetes drug ertugliflozin (brand name STEGLATRO), the VERTIS-CV trial, suggest that ertugliflozin is not superior to placebo in reducing major adverse cardiovascular events (MACE) but may reduce the rate of hospitalization for heart failure.  Read more

FDA Removes Amputation Warning for Invokana

Based on recent review of studies showing that the diabetes drug canagliflozin (Invokana) has many benefits for heart and kidney disease, and that the risk of amputation, while still increased with canagliflozin, is lower than previously described, the FDA has concluded that the boxed warning for increased amputation risk should be removed.  It is still important […]

A New “Heat-Tethered” Method of Dual Drug Administration

Researchers from Duke University have demonstrated that a type 2 diabetes treatment combining two drugs is more effective when the drugs are linked by a heat-sensitive tether, instead of simply being administered at the same time. Read more

Dapagliflozin Approved to Treat Heart Failure

The DAPA-HF trial provided evidence for improved mortality and morbidity benefits when using the diabetes drug dapagliflozin, in combination with normal standards of care, for patients with heart failure and reduced left ventricular fraction. Read more

Bayshore Pharmaceuticals Joins Metformin Recall List

Bayshore becomes the sixth pharma company to issue a recall for the popular diabetes drug metformin, after the FDA found high levels of N-nitrosodimethylamine (NDMA), a probably carcinogen, in tested samples. The recall is for one lot each of the 500- and 750-milligram extended-release metformin. Read more

DPP-4 Inhibitors Linked to Rare Skin Condition

Researchers say that the class of diabetes drugs called DPP-4 inhibitors, which includes include sitagliptin, saxagliptin, linagliptin, and alogliptin, may be linked to a rare skin condition called bullous pemphigoid, which causes large, fluid-filled blisters due to an abnormal immune system response. Read more

FDA “Fast-Tracks” Farxiga for Heart Failure Benefits

Research has shown that diabetes drugs in the SGLT2 inhibitor class can have cardiovascular benefits. Now the FDA has given a Fast Track Designation to accelerate study of how one of these drugs, Farxiga (dapagliflozin) may help reduce death and heart failure after a heart attack. Read more

Statins Reduce Mortality Risk in Older Patients

Heart disease is more life-threatening in older patients than younger population or middle-aged patients. Prevention strategies, including using lifestyle modification and statins, are gaining increasing importance among physicians. A study on statin use in veterans 75 years or older found that statins were associated with overall reduced risk of disease and death. Read more

Oral Semaglutide Effective Paired with Insulin

Multiple studies have been conducted to evaluate the performance of oral semaglutide, which is the first oral medication in the glucagon-like peptide-1 (GLP-1) receptor agonist drug class. The PIONEER 8 trial found reductions in A1c and body weight when oral semaglutide is paired with various insulin regimens. Read more

ACE Inhibitor Captopril May Cause Problems in COVID-19

Captopril, an ACE inhibitor drug, seems to be associated with a higher rate of adverse pulmonary reactions in patients with diabetes than other ACE inhibitors or angiotensin receptor blockers (ARBs). ACE inhibitors are commonly used to treat heart and kidney conditions, which are often comorbid with diabetes. A different ACE inhibitor may be a better […]